2月5日，海翔药业（002099）发布公告，公司此前出资1亿元人民币，占合伙企业杭州复宏股权投资合伙企业（有限合伙）64.10%的合伙份额，该合伙企业专门投资于复宏汉霖（02696）的非上市股份。根据最新进展，合伙企业持有的复宏汉霖457万股境内未上市股份已于2026年2月4日完成转换为H股，并在香港联交所上市。2025年前三季度，海翔药业实现收入13.67亿元，归母净利润729万元。
Source Link2月5日，海翔药业（002099）发布公告，公司此前出资1亿元人民币，占合伙企业杭州复宏股权投资合伙企业（有限合伙）64.10%的合伙份额，该合伙企业专门投资于复宏汉霖（02696）的非上市股份。根据最新进展，合伙企业持有的复宏汉霖457万股境内未上市股份已于2026年2月4日完成转换为H股，并在香港联交所上市。2025年前三季度，海翔药业实现收入13.67亿元，归母净利润729万元。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.